A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects With a Rising PSA Following Definitive Local Therapy.
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Docetaxel (Primary) ; Bicalutamide; Leuprorelin
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 10 Jun 2017 Biomarkers information updated
- 21 Nov 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004048)
- 01 Sep 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.